An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging

Phase 3

Completed

Conditions: Liver Lesions

Interventions: Drug: SonoVue®
Drug: Sonazoid™

Registration Number: NCT03335566

Lead Sponsor: GE Healthcare

Brief Summary: The purpose of this study is to compare the efficacy of Sonazoid™ and SonoVue® in participants with focal liver lesions (FLLs), by comparing pre-and post-contrast ultrasound examination findings with regard to various aspects of lesion diagnosis including diagnosis as benign versus malignant, specific lesion diagnosis, confidence in diagnosis, and quality of delineation of lesion-related blood vessels (from images obtained during vascular imaging) and detection of lesion presence and quality of delineation of the whole liver (from images obtained during whole liver imaging).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 424

Inclusion Criteria

Participants may be included in the study if they meet all of the following criteria:

Participant has at least 1 untreated focal liver lesions (FLL) but =<8 lesions (excluding cysts) <10 centimeter (cm) in diameter confirmed in a diagnostic examination performed in the past month (or past 3 months if lesion is benign) that can be visualised by non- contrast-enhanced (CE) ultrasound
Participant has had a dynamic CE-computed tomography (CE-CT) or CE-magnetic resonance imaging (CE-MRI) examination within the past month or is scheduled to have one in the month following inclusion in the study and the original images (or copies thereof) are/will be available. (This inclusion criterion does not apply for participants enrolled as training cases. Investigators will be asked to submit standard of truth/ reference diagnosis for training cases whenever possible, since the cases may be used for training and testing the blinded readers prior to the blinded read)
Participant is a 20- to 80-year-old inpatient or outpatient referred for an ultrasound examination of the liver
Participant is able and willing to comply with study procedures and will give their signed and dated informed consent
The participant, if female, is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed on the day of investigational medicinal product (IMP) administration (with the result known before IMP administration), are negative

Exclusion Criteria

The participant has an acute clinically fatal condition (i.e., not expected to survive for at least 6 months)
The participant has previously received Sonazoid™ or has received SonoVue® within the past 30 days
The participant has undergone or is undergoing systemic or loco-regional chemotherapy, or radiation therapy
The participant is participating in another clinical trial with an unregistered medicinal product, or less than 30 days have passed since completing participation in such a trial
The participant has a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension or shock)
The participant has known hypersensitivity to sulphur hexafluoride or to any of the components of SonoVue®
The participant has undergone or plans to undergo liver biopsy or surgery within the 24 hours before or after this examination
The participant has undergone or plans to undergo an examination with a contrast agent (i.e., iodinated x-ray contrast agent, magnetic resonance imaging (MRI) contrast agent or another ultrasound contrast agent) within the 24 hours before or after this examination
The participant is considered to be unsuitable to participate in the study by the investigator
The participant is known to have a right-to-left shunt, severe pulmonary hypertension (pulmonary artery pressure >90 millimeter of mercury (mmHg) or uncontrolled systemic hypertension
The participant has a recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within the last 7 days, significant worsening of cardiac symptoms within the last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of electrocardiogram [ECG], laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders
The participant has adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli
The participant has known thrombosis within the liver, portal, or mesenteric veins

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SonoVue®	SonoVue®	Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
Sonazoid™	Sonazoid™	Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or Benign Against the Reference Diagnosis (RD)/Standard of Truth	Pre-administration up to 15 minutes post-administration	Accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessments were done by 3 blinded readers. Efficacy population which included all participants who received Sonazoid™ or SonoVue®, for whom pre-contrast \& post-contrast images were recorded, \& for whom there was a reference standard contrast-enhanced computed tomography (CECT)/contrast-enhanced magnetic resonance imaging (CE-MRI) examination or biopsy.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Accuracy Improvement in Post-contrast Versus Pre-contrast Ultrasound Examination for Lesion-Specific Diagnoses of the Target Lesion Against the Reference Diagnosis/Standard of Truth	Pre-administration up to 15 minutes post-administration	The accuracy improvement was calculated by the number of participants with improved diagnoses from the pre-contrast diagnosis to the post-contrast diagnosis divided by the total number of participants, multiplied by 100. Assessment was performed by 3 blinded readers.
Number of Lesions Detected by Post-Contrast US Relative to Number of Lesions Detected by Pre-Contrast US (Both by Blinded Readers[BR]) and Number of Lesions Detected by Post-Contrast US (by BR) Relative to Number of Lesions Detected by RD (Investigators)	Pre-administration up to 15 minutes post-administration	For the cases that can be assessed by the blinded readers both pre- and post-contrast, differences were calculated between the Sonazoid™ and SonoVue® groups in the number of lesions detected during whole-liver imaging (post-contrast minus pre-contrast). The differences were also calculated between the Sonazoid™ and SonoVue® groups in the number of lesions (post-contrast minus reference diagnosis) detected during whole-liver imaging.
Number of Participants With Diagnostic Confidence (Evaluated by Blinded Readers) in Pre-Contrast and Post-Contrast Ultrasound Examination Results	Pre-administration up to 15 minutes post-administration	Confidence in diagnoses from the pre- and post-contrast ultrasound examinations was evaluated based on 4-point scale: 0-Unknown (cannot make a judgement on level of confidence), 1- Not confident (another examination was required), 2- Probable (Would have more confidence if another diagnostic imaging test such as MRI or CT was performed), 3- Definite (Sufficient confidence to the extent that another diagnostic imaging test such as MRI or CT was unnecessary).

Trial Locations

Locations (18): Chinese PLA General Hospital, No. 28 Fuxing Road
🇨🇳
Haidan, Beijing, China
Peking Union Medical College Hospital, East Campus: No.1 Shuaifuyuan Wangfujing
🇨🇳
Dongcheng, Beijing, China
Peking Union Medical College Hospital, West Campus: No. 41 Damucang Hutong
🇨🇳
Xicheng, Beijing, China
The First Affiliated Hospital, Sun-Yat sen University, No. 58 Zhongshan Second Road
🇨🇳
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Zhongshan University, No. 107 Yanjiang West Road
🇨🇳
Guangzhou, Guangdong, China
Shanghai First Hospital, South Campus: No.650 New Songjiang Road
🇨🇳
Songjiang, Shanghai, China
Shanghai First Hospital, North Campus: No. 100 Haining Road
🇨🇳
Hongkou, Shanghai, China
Zhongshan Hospital Fudan University, No. 180 Fenglin Road
🇨🇳
Xuhui, Shanghai, China
Shanghai Sixth Hospital, No. 600 Yishan Road
🇨🇳
Xuhui, Shanghai, China
Shanghai Hua Shan Hospital, No. 12 Wulumuqi Middle Road
🇨🇳
Xuhui, Shanghai, China
Shanghai Tenth People's Hospital, No. 301 Yanchang Middle Road
🇨🇳
Zhabei, Shanghai, China
Seoul National University Hospital, 101, Daehak-Ro, Jongno-Gu
🇰🇷
Seoul, Korea, Republic of
Seoul St Mary's Hospital, 222 Banpo-daero, Seocho-gu
🇰🇷
Seoul, Korea, Republic of
National Taiwan University Hospital - Yunlin Branch, No. 579, Sec. 2 Yunlin Road
🇨🇳
Douliu, Yunlin County, Taiwan
National Taiwan University Hospital, No. 7 Chung-Shan South Road
🇨🇳
Taipei, Taiwan
Taipei Veterans General Hospital, No. 201 Shih-Pai Road, Sec. 2
🇨🇳
Taipei, Taiwan
Mackay Memorial Hospital, No. 92, Sec. 2 Zhongshan N. Road
🇨🇳
Taipei, Taiwan
Cathay General Hospital, No. 280 Jen-Ai Road, Sec. 4
🇨🇳
Taipei, Taiwan